NASDAQ:NGNE Neurogene (NGNE) Stock Price, News & Analysis $35.00 +0.62 (+1.80%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$32.47▼$36.6350-Day Range$32.82▼$45.9552-Week Range$12.49▼$53.00Volume89,332 shsAverage Volume118,014 shsMarket Capitalization$454.30 millionP/E RatioN/ADividend YieldN/APrice Target$51.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Neurogene alerts: Email Address Neurogene MarketRank™ Stock AnalysisAnalyst RatingBuy3.11 Rating ScoreUpside/Downside45.7% Upside$51.00 Price TargetShort InterestBearish16.93% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.67Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.47) to ($4.31) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.12 out of 5 starsMedical Sector735th out of 910 stocksPharmaceutical Preparations Industry348th out of 426 stocks 3.6 Analyst's Opinion Consensus RatingNeurogene has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageNeurogene has only been the subject of 4 research reports in the past 90 days.Read more about Neurogene's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted16.93% of the float of Neurogene has been sold short.Short Interest Ratio / Days to CoverNeurogene has a short interest ratio ("days to cover") of 13.6, which indicates bearish sentiment.Change versus previous monthShort interest in Neurogene has recently increased by 11.54%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNeurogene does not currently pay a dividend.Dividend GrowthNeurogene does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NGNE. Previous Next 2.6 News and Social Media Coverage News SentimentNeurogene has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Neurogene this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for NGNE on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Neurogene insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.92% of the stock of Neurogene is held by insiders.Percentage Held by Institutions52.37% of the stock of Neurogene is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Neurogene's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Neurogene are expected to grow in the coming year, from ($4.47) to ($4.31) per share.Price to Book Value per Share RatioNeurogene has a P/B Ratio of 2.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Neurogene's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Golden CrestBiden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.>> Get Your FREE Wealth Protection Guide << About Neurogene Stock (NASDAQ:NGNE)Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.Read More NGNE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NGNE Stock News HeadlinesSeptember 6 at 1:13 AM | americanbankingnews.comBrokerages Set Neurogene Inc. (NASDAQ:NGNE) PT at $51.00August 17, 2024 | finance.yahoo.comNeurogene's (NASDAQ:NGNE) Earnings Might Be Weaker Than You ThinkSeptember 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.August 15, 2024 | markets.businessinsider.comBuy Rating for Neurogene: Promising Rett Syndrome Program and Strong Financial OutlookAugust 13, 2024 | markets.businessinsider.comBuy Rating on Neurogene Backed by Strong 2Q24 Earnings and Promising Pipeline ProgressAugust 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for Neurogene Amid Promising Outlook for Gene Therapy Candidate NGN-401August 13, 2024 | markets.businessinsider.comBuy Rating for Neurogene Based on Strong Clinical Prospects and Technological AdvantagesAugust 10, 2024 | finance.yahoo.comNeurogene Reports Second Quarter 2024 Financial Results and Highlights Recent UpdatesSeptember 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.August 10, 2024 | markets.businessinsider.comNeurogene Secures RMAT Designation and Joins FDA START Program, Analyst Maintains Buy RatingAugust 7, 2024 | finance.yahoo.comNeurogene Announces RMAT Designation for NGN-401 Investigational Gene Therapy for Rett SyndromeAugust 7, 2024 | nasdaq.comNeurogene Rings the Opening BellJune 18, 2024 | businesswire.comNeurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett SyndromeJune 5, 2024 | businesswire.comNeurogene to Participate in Upcoming ConferencesMay 14, 2024 | markets.businessinsider.comNeurogene’s Strong Pipeline and Financial Health Prompt Buy RatingMay 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for Neurogene Amid Positive Outlook on NGN-401 and EXACT TechnologyMay 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Xencor (XNCR) and Neurogene (NGNE)May 10, 2024 | investorplace.comNGNE Stock Earnings: Neurogene Beats EPS for Q1 2024See More Headlines Receive NGNE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neurogene and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/09/2024Today9/07/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NGNE Previous SymbolNASDAQ:NGNE CUSIPN/A CIK1404644 Webwww.neurogene.com Phone(877) 237-5020Fax778-331-4486Employees90Year FoundedN/APrice Target and Rating Average Stock Price Target$51.00 High Stock Price Target$65.00 Low Stock Price Target$31.00 Potential Upside/Downside+45.7%Consensus RatingBuy Rating Score (0-4)3.11 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,320,000.00 Net MarginsN/A Pretax Margin-5,146.70% Return on Equity-32.44% Return on Assets-27.70% Debt Debt-to-Equity RatioN/A Current Ratio12.17 Quick Ratio12.17 Sales & Book Value Annual Sales$925,000.00 Price / Sales491.14 Cash FlowN/A Price / Cash FlowN/A Book Value$11.93 per share Price / Book2.93Miscellaneous Outstanding Shares12,980,000Free Float11,692,000Market Cap$454.30 million OptionableOptionable Beta1.49 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Rachel L. McMinn Ph.D. (Age 51)Founder, Executive Chair & CEO Comp: $676.54kMs. Christine Mikail Cvijic J.D. (Age 46)President, CFO & Corporate Secretary Comp: $623.29kDr. Stuart Cobb Ph.D. (Age 54)Chief Scientific Officer Comp: $478.81kMr. Arvind SreedharanSenior Vice President of Business OperationsMs. Donna M. Cochener-Metcalfe J.D. (Age 49)Senior VP & General Counsel Dr. Effie Albanis M.D.Senior Vice President of Early Clinical & Translational ResearchDr. Andrew E. Mulberg CPIFAAP, M.D., Senior Vice President of Regulatory Affairs, Quality Assurance & Quality ControlMr. Ricardo JimenezSenior Vice President of Technical OperationsDr. Julie Jordan M.D. (Age 52)Chief Medical Officer More ExecutivesKey CompetitorsGalapagosNASDAQ:GLPGKiniksa PharmaceuticalsNASDAQ:KNSAAkero TherapeuticsNASDAQ:AKROArvinasNASDAQ:ARVNImmunocoreNASDAQ:IMCRView All CompetitorsInstitutional OwnershipDriehaus Capital Management LLCBought 56,533 shares on 8/16/2024Ownership: 0.787%Integral Health Asset Management LLCBought 70,000 shares on 8/14/2024Ownership: 0.539%Marshall Wace LLPBought 11,229 shares on 8/14/2024Ownership: 0.319%Avoro Capital Advisors LLCBought 22,029 shares on 8/14/2024Ownership: 0.170%Renaissance Technologies LLCSold 5,900 shares on 8/9/2024Ownership: 0.407%View All Institutional Transactions NGNE Stock Analysis - Frequently Asked Questions How have NGNE shares performed this year? Neurogene's stock was trading at $19.38 at the start of the year. Since then, NGNE stock has increased by 80.6% and is now trading at $35.00. View the best growth stocks for 2024 here. How were Neurogene's earnings last quarter? Neurogene Inc. (NASDAQ:NGNE) posted its earnings results on Friday, August, 9th. The company reported ($1.09) earnings per share for the quarter, missing analysts' consensus estimates of ($1.02) by $0.07. The firm earned $0.93 million during the quarter. Who are Neurogene's major shareholders? Neurogene's top institutional investors include Driehaus Capital Management LLC (0.79%), Integral Health Asset Management LLC (0.54%), Renaissance Technologies LLC (0.41%) and Marshall Wace LLP (0.32%). How do I buy shares of Neurogene? Shares of NGNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NGNE) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurogene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurogene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.